2023
Dysregulation of the endogenous cannabinoid system following opioid exposure
Mohammad Aghaei A, Saali A, Canas M, Weleff J, D'Souza D, Angarita G, Bassir Nia A. Dysregulation of the endogenous cannabinoid system following opioid exposure. Psychiatry Research 2023, 330: 115586. PMID: 37931479, PMCID: PMC10842415, DOI: 10.1016/j.psychres.2023.115586.Peer-Reviewed Original ResearchConceptsEndocannabinoid systemECS componentsBrain regionsNovel neurobiological targetsTreatment of OUDEndogenous opioid systemOpioid-related deathsEndogenous cannabinoid systemSpecific brain regionsECS dysregulationOpioid exposureOUD treatmentOpioid systemCannabinoid systemNeurobiological targetsNew medicationsPreclinical literatureCannabinoid receptorsEndogenous ligandTherapeutic potentialStudy typePresent potential targetsExposure protocolOpioidsPreclinical research
2022
Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
D’Souza D, DiForti M, Ganesh S, George TP, Hall W, Hjorthøj C, Howes O, Keshavan M, Murray RM, Nguyen TB, Pearlson GD, Ranganathan M, Selloni A, Solowij N, Spinazzola E. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. The World Journal Of Biological Psychiatry 2022, 23: 719-742. PMID: 35315315, DOI: 10.1080/15622975.2022.2038797.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsWFSBP Task ForceRisk of psychosisAge of exposureRates of psychosisRecurrent psychosisTask ForceEndocannabinoid systemPsychosis outcomesConsensus paperHigh riskPsychotic disordersPsychotic statesPsychosisPotency of cannabisCriteria of causalityCannabisCannabinoidsLines of evidenceCannabis lawsRiskExposureDisordersEvidenceConfoundersIllness
2020
In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers
Schindler EAD, Schnakenberg Martin AM, Sewell RA, Ranganathan M, DeForest A, Pittman BP, Perrino A, D’Souza D. In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers. Psychopharmacology 2020, 237: 3097-3107. PMID: 32632491, DOI: 10.1007/s00213-020-05595-9.Peer-Reviewed Original ResearchConceptsCapsaicin-induced hyperalgesiaCross-over studyHealthy human subjectsIntravenous THCAcute painAntinociceptive effectDrug effectsDrug AdministrationHuman subjectsDose-related mannerPeak drug effectHealthy human volunteersSignificant antinociceptive propertiesRationaleAnimal studiesElectrical painPain conditionsPain managementChemical painPain ratingsAntinociceptive propertiesHealthy volunteersPsychoactive dosesAcute chemicalHuman studiesCognitive alterations
2018
The Psychiatric Consequences of Cannabinoids
De Aquino JP, Sherif M, Radhakrishnan R, Cahill JD, Ranganathan M, D'Souza D. The Psychiatric Consequences of Cannabinoids. Clinical Therapeutics 2018, 40: 1448-1456. PMID: 29678279, DOI: 10.1016/j.clinthera.2018.03.013.Peer-Reviewed Original ResearchConceptsPsychiatric effectsPsychiatric disordersPre-existing psychiatric disordersCannabis useLong-term brain changesRates of cannabisNegative psychiatric outcomesNegative psychiatric effectsDose-dependent effectPublic mental healthCannabinoid exposureWithdrawal syndromeCannabis exposureAcute effectsBrain changesMood disordersPsychiatric outcomesGeneral populationPsychomotor functionHealthy individualsMedical cannabisPsychiatric consequencesChronic exposureSignificant impairmentMental health
2016
A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications.
Wilkinson ST, Radhakrishnan R, D'Souza DC. A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. The Journal Of Clinical Psychiatry 2016, 77: 1050-64. PMID: 27561138, DOI: 10.4088/jcp.15r10036.BooksConceptsEfficacy of marijuanaPosttraumatic stress disorderPsychiatric indicationsStrength of evidenceTourette's disorderPsychiatric conditionsSystematic reviewAlzheimer's diseaseChronic cannabinoid exposureEfficacy of cannabinoidsUse of cannabinoidsAbsence of RCTsMedical marijuanaEmergence of psychosisLow-quality studiesBest available evidenceSafety of marijuanaPersistent marijuana useCannabinoid exposureClinical trialsPRISMA guidelinesSide effectsSpecific diagnosisGRADE methodsConstituent cannabinoidsMarijuana and Madness: Associations Between Cannabinoids and Psychosis
Ranganathan M, Skosnik PD, D’Souza D. Marijuana and Madness: Associations Between Cannabinoids and Psychosis. Biological Psychiatry 2016, 79: 511-513. PMID: 26970361, DOI: 10.1016/j.biopsych.2016.02.007.Peer-Reviewed Original ResearchHuman Laboratory Studies on Cannabinoids and Psychosis
Sherif M, Radhakrishnan R, D’Souza D, Ranganathan M. Human Laboratory Studies on Cannabinoids and Psychosis. Biological Psychiatry 2016, 79: 526-538. PMID: 26970363, DOI: 10.1016/j.biopsych.2016.01.011.BooksConceptsCannabinoid agonistsPsychotomimetic effectsAcute psychotomimetic effectsHealthy control subjectsCrossover laboratory studyEffects of ketamineHuman laboratory studiesGamma-aminobutyric acidHealthy human subjectsSelf-medication hypothesisTransient exacerbationAntipsychotic medicationControl subjectsDopamine metabolismGlutamate systemDopamine releasePsychotomimetic drugsCognitive symptomsDrug AdministrationAgonistsMagnitude of effectSymptomsSchizophreniaCannabinoidsLaboratory studies
2014
Disrupted Gamma-Band Neural Oscillations During Coherent Motion Perception in Heavy Cannabis Users
Skosnik PD, Krishnan GP, D'Souza DC, Hetrick WP, O'Donnell BF. Disrupted Gamma-Band Neural Oscillations During Coherent Motion Perception in Heavy Cannabis Users. Neuropsychopharmacology 2014, 39: 3087-3099. PMID: 24990428, PMCID: PMC4229582, DOI: 10.1038/npp.2014.166.Peer-Reviewed Original Research
2013
Spicing things up: synthetic cannabinoids
Spaderna M, Addy PH, D’Souza D. Spicing things up: synthetic cannabinoids. Psychopharmacology 2013, 228: 525-540. PMID: 23836028, PMCID: PMC3799955, DOI: 10.1007/s00213-013-3188-4.Peer-Reviewed Original ResearchCommentary on Hermanns‐Clausen et al. (2013): Spicing things up – the emerging phenomenon of synthetic cannabinoid use
Addy PH, D'Souza D. Commentary on Hermanns‐Clausen et al. (2013): Spicing things up – the emerging phenomenon of synthetic cannabinoid use. Addiction 2013, 108: 545-546. PMID: 23418659, DOI: 10.1111/add.12098.Peer-Reviewed Original Research
2012
The Effect of Chronic Cannabinoids on Broadband EEG Neural Oscillations in Humans
Skosnik PD, D'Souza DC, Steinmetz AB, Edwards CR, Vollmer JM, Hetrick WP, O'Donnell BF. The Effect of Chronic Cannabinoids on Broadband EEG Neural Oscillations in Humans. Neuropsychopharmacology 2012, 37: 2184-2193. PMID: 22713908, PMCID: PMC3422484, DOI: 10.1038/npp.2012.65.Peer-Reviewed Original ResearchConceptsNeural oscillationsAuditory steady-state responseCannabis usersCannabis groupGamma rangeChronic cannabis usersCentral cannabinoid-1 receptorsCognitive processesTransient ERPsChronic cannabisChronic cannabinoidsHz powerEEG dataCurrent studyEffects of cannabinoidsCannabisPsychopharmacological effectsExogenous cannabinoidsNaïve controlsElectroencephalographySpectral powerTrial powerEarly ageX frequencyERP
2010
Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofrenia
Sewell RA, Skosnik PD, Garcia-Sosa I, Ranganathan M, D'Souza DC. Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofrenia. Brazilian Journal Of Psychiatry 2010, 32: 515-530. PMID: 20512267, DOI: 10.1590/s1516-44462010000500005.Peer-Reviewed Original ResearchConceptsPsychotic disordersCannabis exposureComponent causesCannabinoid receptor functionCauses of schizophreniaHeavy cannabis exposurePublic health policyCannabinoid exposureTrigger relapsePsychophysiological deficitsCognitive symptomsReceptor functionSchizophreniaHealth policyCannabinoidsLines of evidenceDisordersFurther studiesCannabisSymptomsPsychosisBiological mechanismsExposureIndividual vulnerabilityCause
2009
Cannabinoids and psychosis
Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. International Review Of Psychiatry 2009, 21: 152-162. PMID: 19367509, DOI: 10.1080/09540260902782802.Peer-Reviewed Original ResearchConceptsGeneral populationPsychotic disordersTrigger relapseCannabis usersCognitive symptomsCross-sectional studyIndividual vulnerabilityCannabis useCannabinoid receptor functionLongitudinal studyCase seriesPsychotic illnessPsychotic symptomsCannabisHealthy individualsSchizophreniaPharmacological studiesReceptor functionAutobiographical accountsPsychosisEarly exposureSymptomsTwo-fold increaseConsiderable evidenceComponent causes
2007
Cannabinoids and Psychosis
D'Souza DC. Cannabinoids and Psychosis. International Review Of Neurobiology 2007, 78: 289-326. PMID: 17349865, DOI: 10.1016/s0074-7742(06)78010-2.Peer-Reviewed Original ResearchConceptsReceptor dysfunctionPsychotic disordersTransient psychotic symptomsRecent epidemiological studiesComponent causesRates of cannabisRates of schizophreniaCauses of schizophreniaWarrants further studyAcute psychosisLung cancerCannabis exposureCannabinoid functionHigh riskPsychotic symptomsEpidemiological studiesPeriod of intoxicationPsychosisAvailable evidenceSchizophreniaCannabinoidsGenetic riskBiological plausibilityFurther studiesDysfunction
2006
The acute effects of cannabinoids on memory in humans: a review
Ranganathan M, D’Souza D. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology 2006, 188: 425-444. PMID: 17019571, DOI: 10.1007/s00213-006-0508-y.Peer-Reviewed Original ResearchConceptsStages of memoryHuman literatureDelay-dependent mannerIntrusion errorsMemory taskFree recallPsychological testsAmnestic effectsCognitive functionConstituent cannabinoidsRobust effectMemoryPreclinical literatureFuture researchResultsAcute administrationNeurochemical basisEffects of cannabinoidsDrug useExogenous cannabinoidsIssues of doseAcute effectsLarge bodyLong-term potentiationSmall sample sizeRationaleCannabis
2001
Cannabinoid Antagonists: A Treatment in Search of an Illness
D'Souza D, Kosten T. Cannabinoid Antagonists: A Treatment in Search of an Illness. JAMA Psychiatry 2001, 58: 330-331. PMID: 11296092, DOI: 10.1001/archpsyc.58.4.330.Peer-Reviewed Original Research